Decreased level of serum carnitine might lead to arteriosclerosis progression via the accumulation of advanced glycation end products in maintenance hemodialysis patients

被引:0
|
作者
Kamada Y. [1 ,2 ]
Masuda T. [2 ]
Kotani K. [4 ]
Tanaka S. [2 ]
Nakamura T. [1 ,3 ]
Hamazaki N. [2 ]
Itoh Y. [1 ]
Moriguchi I. [1 ]
Kobayashi N. [1 ]
Okubo M. [1 ]
Takeuchi K. [5 ]
Naito S. [5 ]
Takeuchi Y. [5 ]
机构
[1] Sohbudai Nieren Clinic, Zama
[2] Department of Angiology and Cardiology, Kitasato University, Graduate School of Medical Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa
[3] Department of Rehabilitation Sciences, Kitasato University, Graduate School of Medical Sciences, Sagamihara
[4] Division of Community and Family Medicine, Jichi Medical University, Tochigi
[5] Division of Nephrology, Department of Internal Medicine, Kitasato University, School of Medicine, Sagamihara
关键词
Advanced glycation end products; Arteriosclerosis; Carnitine; Hemodialysis;
D O I
10.1186/s41100-017-0135-6
中图分类号
学科分类号
摘要
Background: Carnitine is reported to improve insulin resistance and reduce oxidative stress. Hyperglycemia and increased oxidative stress are well known to promote the production of advanced glycation end products (AGEs) that can lead to arteriosclerosis in patients with maintenance hemodialysis (HD). In the present study, we aimed to determine whether decreased level of serum carnitine accelerated arteriosclerosis and to clarify the relationships between carnitine, AGEs, and arteriosclerosis in HD patients. Methods: We recruited 116 patients (65 men and 51 women, 62 ± 13 years) undergoing HD three times a week. We measured pre-HD serum free carnitine prior to the first weekly session. AGE level was quantitatively evaluated by measuring skin autofluorescence (SAF) with AGE reader. Arteriosclerosis was evaluated by measuring carotid intima-media thickness (cIMT). Relationships between free carnitine, SAF, and cIMT were analyzed, and significant limiting factors for arteriosclerosis were identified using univariate and multivariate regression analyses. Results: Free carnitine ranged from 14.9 to 53.3 μmol/L (mean, 28.6 ± 8.1 μmol/L). Free carnitine was negatively correlated with SAF (r = - 0.223, P = 0.017) and cIMT (r = - 0.252, P = 0.006). SAF was positively correlated with cIMT (r = 0.263, P = 0.005). Free carnitine was identified as a significant independent limiting factor for cIMT (β = -0.194, P = 0.037). Conclusions: Decreased level of serum carnitine might lead to the progression of arteriosclerosis via the AGE accumulation in HD patients. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [31] SERUM ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS ON HEMODIALYSIS AND CAPD
    ATESHKADI, A
    JOHNSON, CA
    FOUNDS, HW
    ZIMMERMAN, SW
    PERITONEAL DIALYSIS INTERNATIONAL, 1995, 15 (03): : 129 - 133
  • [32] Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?
    Arsov, Stefan
    Graaff, Reindert
    Morariu, Aurora M.
    van Oeveren, Wim
    Smit, Andries J.
    Busletic, Irena
    Trajcevska, Lada
    Selim, Gjulsen
    Dzekova, Pavlina
    Stegmayr, Bernd
    Sikole, Aleksandar
    Rakhorst, Gerhard
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (03) : 885 - 891
  • [33] Skin accumulation of advanced glycation end products is increased in patients with an abdominal aortic aneurysm
    Boersema, Jeltje
    de Vos, Lisanne C.
    Links, Thera P.
    Mulder, Douwe J.
    Smit, Andries J.
    Zeebregts, Clark J.
    Lefrandt, Joop D.
    JOURNAL OF VASCULAR SURGERY, 2017, 66 (06) : 1696 - +
  • [34] PLASMA ADVANCED GLYCOSYLATION END-PRODUCTS IN MAINTENANCE HEMODIALYSIS-PATIENTS
    ODETTI, P
    COSSO, L
    PRONZATO, MA
    DAPINO, D
    GURRERI, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 (11) : 2110 - 2113
  • [35] Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites
    Klemm, A
    Franke, C
    Busch, M
    Müller, A
    Franke, S
    Lang, D
    Passlick-Deetjen, J
    Stein, G
    CLINICAL NEPHROLOGY, 2004, 61 (03) : 191 - 197
  • [36] Decreased Level of Endogenous Secretory Receptor for Advanced Glycation End-Products in Diabetes With Concomitant Hyperlipidemia
    Turk, Z.
    Ljubic, S.
    Boras, J.
    PHYSIOLOGICAL RESEARCH, 2014, 63 (02) : 199 - 205
  • [37] High Serum Advanced Glycation End Products Are Associated with Decreased Insulin Secretion in Patients with Type 2 Diabetes: A Brief Report
    Okura, Tsuyoshi
    Ueta, Etsuko
    Nakamura, Risa
    Fujioka, Yohei
    Sumi, Keisuke
    Matsumoto, Kazuhisa
    Shoji, Kyoko
    Matsuzawa, Kazuhiko
    Izawa, Shoichiro
    Nomi, Yuri
    Mihara, Hitomi
    Otsuka, Yuzuru
    Kato, Masahiko
    Taniguchi, Shin-ichi
    Yamamoto, Kazuhiro
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [38] ADVANCED GLYCATION END PRODUCTS (AGES), CARDIOVASCULAR DISEASE AND CKD-MBD IN HEMODIALYSIS PATIENTS
    Nogueira, Luiz C. F.
    Borges, Cynthia M.
    Franca, Renata A.
    Salani, Talita G.
    Barcelos, Viviane M.
    de Oliveira, Rodrigo B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [39] Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic hemodialysis patients
    Kalousova, Marta
    Jachymova, Marie
    Mestek, Oto
    Hodkova, Magdalena
    Kazderova, Marketa
    Tesar, Vladimir
    Zima, Tomas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 183 - 183
  • [40] Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients
    Kalousova, Marta
    Jachymova, Marie
    Germanova, Alexandra
    Kubena, Ales Antonin
    Tesar, Vladimir
    Zima, Tomas
    KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (01): : 30 - 36